根治性放疗与临床淋巴结阳性前列腺癌的生存
基于美国退伍军人事务部数据库2000至2015年确诊的临床淋巴结阳性非转移性前列腺癌患者,比较雄激素剥夺治疗(ADT)联合放疗与单用ADT的生存差异。ADT联合放疗在基线PSA低于中位数26 ng/mL的患者中与前列腺癌特异性死亡和全因死亡改善相关,而高于中位数者未见此关联。
要点
- 临床淋巴结阳性前列腺癌患者中,ADT联合放疗在基线PSA低于中位数26 ng/mL者与前列腺癌特异性死亡改善相关。
- 基线PSA低于中位数者中,ADT联合放疗与全因死亡改善相关,高于中位数者未见关联。
- 临床淋巴结阳性前列腺癌患者群体异质,部分患者可能通过联合放疗与ADT获得长期生存。
核心结论
- 对于临床淋巴结阳性前列腺癌且基线PSA较低的患者,ADT联合放疗与前列腺癌特异性死亡和全因死亡改善相关。
- 临床淋巴结阳性患者群体异质,其中部分患者可能通过联合放疗与ADT获得长期生存。
研究设计与样本
- 回顾性队列研究,数据来源于美国退伍军人事务部全国数据库,纳入2000至2015年确诊的临床淋巴结阳性非转移性前列腺癌患者。
- ADT组450例,ADT联合放疗组198例。
- 采用多因素竞争风险回归比较前列腺癌特异性死亡,采用Cox回归比较全因死亡,模型纳入ADT联合放疗与PSA水平(以中位数二分)的交互项。
主要发现
- PSA低于中位数26 ng/mL者中,ADT联合放疗与前列腺癌特异性死亡改善相关(亚分布风险比0.50,95%CI 0.28-0.88,P=0.02)。
- PSA高于中位数者中,ADT联合放疗与前列腺癌特异性死亡无显著关联(风险比1.15,95%CI 0.67-1.96,P=0.62)。
- 交互作用检验P=0.038。
- PSA低于中位数者中,ADT联合放疗与全因死亡改善相关(风险比0.38,95%CI 0.25-0.57,P<0.001)。
- PSA高于中位数者中,ADT联合放疗与全因死亡无显著关联(风险比0.91,95%CI 0.60-1.38,P=0.66)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The survival benefit of combined radiation therapy (RT) and androgen deprivation therapy (ADT) compared with ADT alone for clinically lymph node-positive prostate cancer remains controversial. METHODS AND MATERIALS: We identified patients with clinically node-positive, nonmetastatic prostate cancer diagnosed between 2000 and 2015 and treated with ADT (n = 450) or ADT-RT (n = 198) from a national Veterans Affairs database. We compared prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) between treatment groups using multivariable competing-risks regression and Cox regression, respectively. An interaction term between ADT-RT and prostate-specific antigen (PSA) level (dichotomized about the median) was included in the multivariable models. RESULTS: ADT-RT was associated with improved PCSM among patients with PSA levels less than the median of 26 ng/mL (sub-distribution hazard ratio, 0.50; 95% confidence interval [CI] 0.28-0.88; P = .02) but not greater than the median (hazard ratio [HR], 1.15; 95% CI 0.67-1.96; P = .62) (P = .038 for interaction). ADT-RT was also associated with improved ACM among patients with PSA levels less than the median (HR, 0.38; 95% CI 0.25-0.57; P < .001) but not greater than the median (HR, 0.91; 95% CI 0.60-1.38; P = .66) (P = .004 for interaction). CONCLUSIONS: Definitive treatment with ADT-RT is associated with improved PCSM and ACM among patients with clinically node-positive prostate cancer and lower baseline PSA levels. Patients with clinically node-positive disease appear to be a heterogeneous cohort, with a subset who may achieve long-term survival with combined RT and ADT.
引用
- Bryant AK, Kader AK, McKay RR, et al. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29891203. doi:10.1016/j.ijrobp.2018.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。